https://www.selleckchem.com/pr....oducts/3,4-dichlorop
05) in comparison with the control group at 1 year. There was no increase of serum CA125 in both groups, and no recurrence of neoplasia or lymphadenopathy was detected. No adverse reactions were recorded. In addition, no changes were detected after FIR treatment for fibroblast, A2780, SKOV-3, HELA, and Ishikawa cells in cell viability, proliferation, apoptosis, and cell cycle. Conclusion FIR can be used to treat patients with GCRL following gynecological cancer treatment. Following clinical and experimental stu
Like
Comment
Share
